Humanigen, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies that prevent and manage an overactive immune response. At the forefront of its pipeline is lenzilumab, a monoclonal antibody designed to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF) by binding to it. This drug has been investigated for mitigating the cytokine storm in COVID-19 patients, having successfully completed a Phase 3 trial. It is also currently being evaluated in a Phase 2/3 study supported by the NIH. Furthermore, lenzilumab's potential extends to various other conditions: it is being explored in conjunction with CD19-targeted CAR-T cell therapies and for several inflammatory disorders, including acute Graft versus Host Disease (GvHD) following allogeneic hematopoietic stem cell transplantation, eosinophilic asthma, and rheumatoid arthritis. The company is also investigating its use in chronic myelomonocytic leukemia (CMML) for individuals with RAS pathway mutations. Beyond lenzilumab, Humanigen's pipeline features additional 'Humaneered' monoclonal antibodies. These include ifabotuzumab, which binds to EphA3, and HGEN005, designed to target EMR1. HGEN005 is under development for various eosinophilic conditions, such as eosinophilic leukemia, both as a standalone antibody and as a foundational component for innovative CAR-T constructs. Established in 2000 and based in Short Hills, New Jersey, Humanigen, Inc. recently announced a significant corporate development: on January 3, 2024, the company voluntarily filed for Chapter 11 reorganization in the U.S. Bankruptcy Court for the District of Delaware.